Results 1 to 10 of about 64,353 (271)

Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study [PDF]

Therapeutic Advances in Medical Oncology
Background: Mesothelioma is a rare and highly aggressive tumor that causes severe damage. However, there is a lack of systematic reports on the incidence and clinical characteristics of mesothelioma in the Chinese population.
Shengjie Yang, Yue Hao, Ke Wang, Haipeng Xu, Long Huang, Ling Xu, Rui Meng, Bihui Li, Jianhui Huang, Youcai Zhu, Xuefei Shi, Dong Wang, Ziyan Yang, Zhenying Guo, Jingxun Wu, Wenfeng Li, Jianfei Fu, Yinghua Ji, Zongyang Yu, Miao Li, Huijing Feng, Lin Wang, Qing Ji, Wenjun Tang, Zhengbo Song, Chunwei Xu, Qian Wang   +26 more
doaj   +2 more sources

Malignant mesothelioma in rare sites: two case reports [PDF]

Frontiers in Oncology
Mesothelioma is a rare tumor originating from mesothelial cells in the pleura or other sites. Malignant pleural mesothelioma (MPM) is the most common aggressive type of mesothelioma (accounting for 81%) and carries a poor prognosis (median OS: 1 year ...
Qiguang Du, Jialu Guo, Zi Zhu, Yutong Zhang, He Cui, Zhongkai Xu, Rang Yang, Wenlong Liang   +7 more
doaj   +2 more sources

Malignant pleural mesothelioma patients’ experience by gender: findings from a cross-sectional UK-national questionnaire

BMJ Open Respiratory Research, 2022
Objectives Malignant mesothelioma is an aggressive malignancy of mesothelial surfaces, most commonly those of the pleura. The aim of this study was to understand, using a national questionnaire, the gendered care experiences of patients with malignant ...
Liz Darlison, Lorraine Creech, Angela Tod, Michaela Senek, Steve Robertson   +4 more
doaj   +1 more source

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

EClinicalMedicine, 2022
Summary: Background: Currently, there is no US Food and Drug Administration approved therapy for patients with pleural mesothelioma who have relapsed following platinum-doublet based chemotherapy. Vinorelbine has demonstrated useful clinical activity in
Dean A. Fennell, Catharine Porter, Jason Lester, Sarah Danson, Paul Taylor, Michael Sheaff, Robin M Rudd, Aarti Gaba, Sara Busacca, Lisette Nixon, Georgina Gardner, Liz Darlison, Charlotte Poile, Cathy Richards, Peter-Wells Jordan, Gareth Griffiths, Angela Casbard   +16 more
doaj   +1 more source

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma

Nature Communications, 2021
Delineation of the genomic complexities of malignant pleural mesothelioma (MPM) has lagged behind other malignancies. Zhang et al. meaningfully add to our understanding of MPM, and their findings emphasize the need to combine drug development efforts ...
Marjorie G. Zauderer
doaj   +1 more source

Must countries shoulder the burden of mesothelioma to ban asbestos? A global assessment

BMJ Global Health, 2022
Introduction Mesothelioma is a key asbestos-related disease (ARD) but can be difficult to diagnose. Countries presumably ban asbestos to reduce future ARD burdens, but it is unknown if countries ban asbestos as a consequence of ARD burdens.
Seong-Kyu Kang, Ro-ting Lin, Sonja Klebe, Ken Takahashi, Odgerel Chimed-Ochir, Anna K Nowak, Tatsuhiko Kubo, Sugio Furuya, Emma M Rath, Yui Yumiya, Kim Brislane   +10 more
doaj   +1 more source

Understanding clinical decision-making in mesothelioma care: a mixed methods study

BMJ Open Respiratory Research, 2022
Introduction Malignant pleural mesothelioma is a rare, incurable cancer arising from previous asbestos exposure; patients have a poor prognosis, with a median survival rate of 8–14 months. Variation in mesothelioma clinical decision-making remains common
Najib Rahman, Catherine Henshall, Edward McKeown, Zoe Davey, Helen Walthall, Hannah Ball, Mitra Shahidi, John Park, Paul Dawson, Anand Sundralingam   +9 more
doaj   +1 more source

Mitochondrial ROS Induce Partial Dedifferentiation of Human Mesothelioma via Upregulation of NANOG

Antioxidants, 2020
The expression of pluripotency factors is a key regulator of tumor differentiation status and cancer stem cells. The purpose of this study was to examine the expression of pluripotency factors and differentiation status of human mesothelioma and the role
Filip Sedlic, Fran Seiwerth, Ana Sepac, Suncana Sikiric, Marina Cindric, Marija Milavic, Lovorka Batelja Vuletic, Marko Jakopovic, Sven Seiwerth   +8 more
doaj   +1 more source

Meet the researchers: an alternative method of engaging patients with research in mesothelioma

Research Involvement and Engagement, 2018
Plain English summary There are new ways to engage people with science and research but many patient support groups and charitable organisations still hold traditional meetings to provide updates on their activities and to report new developments in ...
Kate Hill, Mags Portman, Zsuzsanna Tabi
doaj   +1 more source

Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033. [PDF]

PLoS ONE, 2017
Malignant mesothelioma is a malignant tumor on the pleura or the peritoneum caused mostly by asbestos. Although asbestos is not currently used in South Korea, the incidence of mesothelioma is increasing due to its long latent period. This study predicted
Kyeong Min Kwak, Domyung Paek, Seung-Sik Hwang, Young-Su Ju   +3 more
doaj   +1 more source